NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - General · USD

Amarin Corporation plc (AMRN) Stock Analysis

Amarin Corporation plc (AMRN) is a Drug Manufacturers - General stock listed on NASDAQ and quoted in US Dollar.

AMRN

$13.63

−$0.08 (−0.58%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AMRN with… →

AMRN Key Statistics

As of Sep 4, 2026
Trading
Open
$13.67
Previous Close
$13.71
Day's Range
13.52–13.85
52-Week Range
12.96–20.90
Volume
80.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.76
Valuation
Market Cap
$287.90M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
13.91
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.81
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.55
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.20
Financials (FY)
Revenue (FY)
$213.65M−6.55%
Net Income (FY)
−$38.80M
Profit marginThe share of revenue left as profit after all costs and taxes.
−14.56%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
21.12M
1-Year Return
−9.31%
Dividend and dates
Earnings Date
October 28, 2026estimated
Avg Volume
79.11K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AMRN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−2.36%
2025+42.45%
2024−43.68%
2023−28.10%
2022−64.09%
2021−31.08%
2020−77.19%
2019+57.53%
2018+239.40%
2017+30.19%
2016 (partial year)−3.45%

As of September 4, 2026.

AMRN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$213.65M−$38.80M−18.2%
2024$228.61M−$82.18M−35.9%
2023$306.91M−$59.11M−19.3%
2022$369.19M−$105.80M−28.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$213.65M$120.87M−$13.94M−$38.80M−18.2%
2024$228.61M$81.38M−$91.80M−$82.18M−35.9%
2023$306.91M$165.54M−$56.62M−$59.11M−19.3%
2022$369.19M$242.48M−$92.34M−$105.80M−28.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AMRN Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricAMRNDrug Manufacturers - General medianvs median
P/S ratio1.553.1351% below
Profit margin−14.56%8.09%22.7 pts below

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Amarin Corporation plc (AMRN) is capitalised at $287.90M on the latest close. It is classified in the Drug Manufacturers - General industry, within the Healthcare sector. The company reports 80 employees.

The 52-week range on file runs from $12.96 to $20.90. The most recent close on file for AMRN is $13.63, dated September 4, 2026. That is −$0.08 (−0.58%) against the previous close. The latest close sits 5.17% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $213.65M. Against the prior fiscal year total of $228.61M, that is a change of −6.55%. The same year closed with a net loss of $38.80M. The reported profit margin is −14.57%. That is 22.7 percentage points below the Drug Manufacturers - General median of 8.09%. Trailing earnings per share are −1.2.

Across the 4 fiscal years on file, revenue moves from $369.19M in 2022 to $213.65M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 13.91. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.81. Measured against sales, the shares trade at 1.55 times revenue. On price-to-sales that is 50.63% below the Drug Manufacturers - General median of 3.13. The medians here are taken across 21 Drug Manufacturers - General companies that report the metric.

Beta against the wider market is reported at 0.76. Daily returns over the trailing 10 years annualize to a volatility of 121.51%. Over the trailing twelve months the price has returned −9.31%. Measured over 10 years, that is −13.54% a year compounded.

Growth & Income

No dividend is on file for AMRN.

Across the complete calendar years on file, 2018 returned +239.40% and 2020 returned −77.19%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is −2.36%.

Peer Comparison

Amarin Corporation plc (AMRN) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Amarin Corporation plc AMRN $287.90M —
Eli Lilly and Company LLY $1.02T 38.6
Johnson & Johnson JNJ $663.28B 32.0
AbbVie Inc. ABBV $453.19B 73.5

The Drug Manufacturers - General industry average P/E ratio is 24.7x. Amarin Corporation plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 NVS

Novartis AG

$304.10B

 AZN

AstraZeneca PLC

$252.33B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

 AMGN

Amgen Inc.

$236.38B

 TMO

Thermo Fisher Scientific Inc.

$226.94B

 NVO

Novo Nordisk A/S

$206.02B

 ABT

Abbott Laboratories

$187.45B
View all Healthcare stocks →

About Amarin Corporation plc

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Visit website →